MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

Lung Neoplasm Malignant Clinical Trial

— MONDRIAN  

Official title:

MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05974475
• Other study ID #: R1842/23-IEO1973
• Status: Recruiting
• Start date: September 11, 2023
• Est. completion date: September 2028

Study information

• Verified date: June 2023
• Source: European Institute of Oncology
• Contact: Stefania Volpe, MD
• Phone: +390257489037
• Email: stefania.volpe[@]ieo.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Stereotactic Body Radiotherapy (SBRT) is a form of high-precision radiotherapy playing a major role in patients diagnosed with early-stage non-small cell lung cancer (NSLCL), especially when surgery cannot be performed. It is a non-invasive, well-tolerated treatment, with an excellent ability to control disease recurrence. However, in some patients, disease response is suboptimal: understanding why this happens may open doors to more aggressive approaches, such as the combination with systemic therapies.

Hence, the goal of this observational trial is to understand which clinical, imaging, and biological factors are associated with response to SBRT through the development of complex models. In other words, the main question it aims to answer is: "Will this patient respond to radiation treatment based on the characteristics of their disease?".

Participants will be treated according to the best clinical practice standards, in agreement with international, national, and internal guidelines.

Researchers will compare data collected from patients treated with SBRT with those collected from a similar group of patients, who will be treated with surgery, to see which factors are actual predictors of response to SBRT, or rather are indicators of more or less aggressive disease behavior.

Description:

The overall planned duration of the study is 60 months.

The project is structured into five main tasks, as following:

• Task 1_Clinical study: Routine clinical data will be collected from eligible patients, including demographics, disease and treatment characteristics, pulmonary function, and blood count parameters.

• Task 2_Radiomics study: Quantitative imaging analysis will be performed on both diagnostic computed tomographies (CTs) and positron emission tomographies (PETs). A software compliant with the Imaging Biomarker Standardization Initiative (IBSI) will be used to extract radiomic features at baseline and at the first clinical progression (or at the last available follow-up, whichever comes first). Clinically established qualitative and semiquantitative metrics (e.g. pleural effusion in CT images and standardized uptake value in PET images) will be retrieved, as well.

• Task 3_Gene expression study: Gene expression profiling will be performed at baseline in both cohorts to investigate the presence of a prognostic pretreatment signature. The analysis will be performed on formalin-fixed paraffin-embedded (FFPE) tissue samples (namely, resected tumor in the surgical cohort and bioptic sample- whenever available- in the SBRT group). A next-generation sequencing (NGS)-based assay which targets 395 immune-related genes and named as Oncomine™ Immune Response Research Assay, will be employed.

• Task 4_Proteomics study: Proteomics will integrate the study of RNA expression performed in Task 3. As in Task 3, the analysis will be performed on FFPE samples, from both patients' cohorts.

• Task 5_Integrative model building: Integration of all previous features in a unique classification model able to determine a precise estimate of individuals with high vs low risk of disease progression and, at the same time, identify relevant predictive factors. The proposed classification model will integrate data from different sources using a multi-layer deep neural network. Federated learning techniques will also be used to reduce the bias due to the choice of a specific trial or data source.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 270
• Est. completion date: September 2028
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven NSCLC; all histologies will be considered eligible (e.g. squamous, adenocarcinoma, large cell carcinoma);

• American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) classification (8th Edition) clinical stage I-II;

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

• No absolute contraindications to either surgery (e.g. severe comorbidities) or SBRT (e.g. active connective diseases, severe pulmonary fibrosis);

• Ability and willingness to sign a written informed consent for treatment and study participation.

Exclusion Criteria:

• Prior diagnosis of invasive cancer (within 3 years before the diagnosis of ES-NSCLC);

• Mental diseases or psychiatric disorders preventing the acquisition of a valid informed consent.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasm Malignant
• Lung Neoplasms
• Neoplasms

Intervention

Radiation:
• SBRT
State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).

Procedure:
• Surgery
State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.

Locations

Country	Name	City	State
Italy	Istituto Europeo di Oncologia (IEO) IRCCS	Milan	Lombardia
Italy	Istituto Europeo di Oncologia IRCCS	Milano	MI

Sponsors (2)

Lead Sponsor	Collaborator
European Institute of Oncology	Associazione Italiana per la Ricerca sul Cancro

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	The time between the beginning of SBRT or date of surgery, and any disease progression (local, regional, distant), death from any cause, or last follow-up, whichever comes first.	24 months